Immune System Diseases

926 trials 377 recruiting

Filter these 926 trials by phase, country and sponsor.

Open in Search →

An extension study to learn if Bimekizumab works and is safe over a long period in adults with Active Axial Spondyloarthritis. Ended

2023-506527-28-00 Axial Spondyloarthritis 5 2020-06-29
A Phase I, First In Human, open-label study of escalating doses of INA03 administered intravenously as single agent in adult patients with r… Ended

2024-518265-10-01 Relapse/ refractory acute Leukemia 1 2020-06-03
Long-term Study of Apremilast (CC-10004) in Pediatric Subjects from 6 Through 17 Years of Age with Moderate to Severe Plaque Psoriasis Ended

2023-503600-83-00 Moderate to Severe Plaque Psoriasis 5 2020-05-27
Evaluation of upadacitinib in adult subjects with axial spondyloarthritis Ended

2022-501018-78-00 Axial Spondyloarthritis 5 2020-03-23
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy Ended

2024-515892-36-00 C3 glomerulopathy 4 2020-01-01
A study to learn if Bimekizumab is safe and works over a long period in adults with Active Psoriatic Arthritis Ended

2023-506528-95-00 Psoriatic Arthritis 5 2019-11-21
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA Ended

2023-507883-38-00 Systemic Juvenile Idiopathic Arthritis 5 2019-11-18
Phase 3b/4 Study in Rheumatoid Arthritis Ended

2023-508022-10-00 Rheumatoid Arthritis 6 2019-07-25
Prospective, randomised, placebo-controlled study of polyvalent intravenous immunoglobulins for the treatment of primary Sjögren's syndrome … Ended

2024-517309-95-00 -Peripheral neuropathy clinically defined: *Pure sensit 5 2019-06-19
A safety and efficacy study of ABT-494 in subjects with Giant Cell Arteritis. Ended

2023-505476-29-00 Giant Cell Arteritis 5 2019-04-05
A Phase 3b, Randomized, Double-blind, Parallel Group, Multicenter Study to Evaluate Further Therapeutic Strategies with Guselkumab in Patien… Ended

2023-508424-34-00 Moderate to Severe Plaque Type Psoriasis 5 2019-02-11
Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD) Ended

2023-507330-24-00 Chronic Graft Versus Host Disease (cGVHD) 9 2019-02-07
Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema) – Measure Up 2 Ended

2022-502936-38-00 Moderate and Severe Atopic Dermatitis 5 2019-01-09
Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema)– Measure Up 1 Ended

2022-502938-30-00 Moderate and Severe Atopic Dermatitis 5 2018-12-10
ORACLE - Randomized Phase 3 Study evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) compared to Investigator’s Choice Ther… Ended

2024-519336-16-00 Relapsed or Refractory Angioimmunoblastic T cell Lympho 10 2018-10-31
A randomized trial to investigate the reset of humoral autoimmunity by combining belimumab with rituximab in severe systemic lupus erythemat… Ended

2023-507867-20-00 Lupus Erythematosus, Systemic 10 2018-10-04
A clinical trial to find out if VAY736 can help people with autoimmune hepatitis, a disease where your immune system attacks your own liver Ended

2023-508859-39-00 Autoimmune hepatitis 10 2018-02-15
KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study Ended

2024-511714-20-00 Multiple Myeloma 4 2018-01-30
A phase I/II, non randomized, monocentric open-label study of autologous CD34+ cells transduced with the G1XCGD lentiviral vector in patient… Ended

2024-512790-27-00 Treatment of X-linked Chronic Granulomatous Disease 7 2016-04-19
A Long-Term, Open-Label, Study for Treatment of JIA Ended

2023-509651-14-00 Juvenile Idiopathic Arthritis (JIA) 10 2013-04-03
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy (PLUTO) Ended

2024-512730-15-00 Systemic Lupus Erythematosus 4 2012-09-14
Immunological and functional characteristics of T memory-like cells in psoriasis under treatment with deucravacitinib. Ended

2024-510759-37-00 Plaque Psoriasis 6
A Study to Investigate Single Ascending Doses of Ocrelizumab for Safety and Side Effects, How The Body Handles It Over A Period of Time, How… Ended

2024-513639-26-00 Multiple Sclerosis (MS) 3
A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preli… Ended

2025-523265-15-00 Seropositive Rheumatoid Arthritis 3